Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06840002 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

StatusRecruiting
PhasePhase 1/2
Started2025-03-18
View on ClinicalTrials.gov ↗
The objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of SHR-A1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian cancer, and to determine the RP2D of the combination, and preliminarily to evaluate the effectiveness of SHR-A1811 combined regimen in the treatment of platinum sensitive recurrent epithelial ovarian cancer.

Amendment history 2 changes detected by DataLookout

2026-09-12
Primary completion pushed: 2026-05 → 2026-12
2026-09-12
Completion pushed: 2026-07 → 2026-12
Trial Details
NCT Number NCT06840002
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Ovarian Cancer
Enrollment 150 participants
Start Date 2025-03-18
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-11